CMPX (Compass Therapeutics) 1-Year Share Buyback Ratio: -30.20% (As of Mar. 2026 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CMPX Compass Therapeutics Inc CMPX
23 GF Score
Price $2.02
! 2 Warning Signs
View Full Analysis

What is Compass Therapeutics 1-Year Share Buyback Ratio?

Compass Therapeutics CMPX -1.70% 23 1-Year Share Buyback Ratio is -30.20 as of Mar. 2026. GuruFocus rates CMPX with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 1,113 Biotechnology companies, Compass Therapeutics ranks worse than 66.22% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Compass Therapeutics's current 1-Year Share Buyback Ratio was -30.20%.

CMPX's 1-Year Share Buyback Ratio is ranked worse than
66.22% of 1113 companies
in the Biotechnology industry
Industry Median: -13.6 vs CMPX: -30.20

Compass Therapeutics  (NAS:CMPX) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Compass Therapeutics 1-Year Share Buyback Ratio Related Terms

CMPX vs XFOR, LRMR, PROK: 1-Year Share Buyback Ratio Comparison

For the Biotechnology subindustry, Compass Therapeutics's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Compass Therapeutics 1-Year Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Compass Therapeutics's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Compass Therapeutics's 1-Year Share Buyback Ratio falls into.


CMPX
23GF Score
Compass Therapeutics Inc CMPX
1-Year Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Compass Therapeutics 1-Year Share Buyback Ratio Calculation

Compass Therapeutics's 1-Year Share Buyback Ratio for the quarter that ended in Mar. 2026 is calculated as

1-Year Share Buyback Ratio=(Shares Outstanding (EOP) (Mar. 2025 ) - Shares Outstanding (EOP) (Mar. 2026 )) / Shares Outstanding (EOP) (Mar. 2025 )
=(138.282 - 180.088) / 138.282
=-30.2%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 1-Year Share Buyback Ratio of -30.20 mean?
Compass Therapeutics (CMPX) has a 1-Year Share Buyback Ratio of -30.20 as of Mar. 2026. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Compass Therapeutics and its competitors. According to the industry distribution chart, Compass Therapeutics ranks #737 out of 1113 companies in the Biotechnology industry, placing it in the top 66.2%.
Is Compass Therapeutics' 1-Year Share Buyback Ratio too high?
Compass Therapeutics' current 1-Year Share Buyback Ratio is -30.20. Based on the distribution chart, Compass Therapeutics ranks #737 out of 1113 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Compass Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Compass Therapeutics' 1-Year Share Buyback Ratio compare to XFOR and LRMR?
According to the Biotechnology industry distribution chart, Compass Therapeutics ranks #737 out of 1113 companies for 1-Year Share Buyback Ratio. This places Compass Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Share Buyback Ratio for a Biotechnology company?
A good 1-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 1-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Share Buyback Ratio mean?
A high 1-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Compass Therapeutics and its competitors. Compass Therapeutics's current 1-Year Share Buyback Ratio is -30.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compass Therapeutics stock overvalued right now?
Compass Therapeutics (CMPX) has a current 1-Year Share Buyback Ratio of -30.20. The current 1-Year Share Buyback Ratio is -30.20. Compass Therapeutics' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Share Buyback Ratio calculated?
1-Year Share Buyback Ratio is calculated from a company's financial statements. For Compass Therapeutics (CMPX), the current 1-Year Share Buyback Ratio is -30.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Compass Therapeutics Business Description

Address 80 Guest Street, Suite 601, Boston, MA, USA, 02135
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
23GF Score

Get the complete analysis for CMPX

1-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.02
Price